Amphotericin B
Product Description
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
Categories
Specifications
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
More Products from QILU PHARMACEUTICAL CO., LTD. (26)
-
Product risankizumab
Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology. -
Product romiplostim
Romiplostim is a TPO receptor agonist peptibody for immune thrombocytopenia (ITP). As the standard second-line therapy with long-acting subcutaneous design, it remains effective in splenectomy-refractory patients, leading the hematology niche market. -
Product secukinumab
Secukinumab is an anti-IL-17A mAb and the pathway leader in psoriasis, ankylosing spondylitis, and psoriatic arthritis. With industry-leading long-term PASI 100 clearance rates, it is a mature, high-volume immunology asset with stable market share. -
Product trastuzumab deruxtecan
Trastuzumab deruxtecan is a HER2-directed ADC that pioneered therapy for HER2-low breast cancer. The DESTINY program has reshaped global guidelines, with massive cross-tumor potential across breast, gastric, and lung cancers, setting the ADC technology benchmark. -
Product vedolizumab
Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics. -
Product Abaloparatide
Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b... -
Product Aprepitant
Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5... -
Product atezolizumab
Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape. -
Product bevacizumab
Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape. -
Product Bupivacaine
Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action... -
Product daratumumab
Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment. -
Product denosumab
Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology.